Physician profile
Ivan R Lopez
NPI 1992845069
$8,561.25
in general payments reported to CMS, 2019-2025
20 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $536 · 2021: $1,174 · 2022: $685 · 2023: $1,266 · 2024: $2,195 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,581.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,504.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $1,247.70 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $1,158.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $810.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $631.57 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $628.09 | 2020-2022 | |
| Amgen INC. | $450.00 | 2024-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.86 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $322.20 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $154.69 | 2020-2021 | |
| Exact Sciences Corporation | $114.23 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $53.17 | 2020-2024 | Immunocap |
| Amarin Pharma, INC. | $21.36 | 2021 | |
| Glaxosmithkline, LLC. | $19.50 | 2023 | Rotarix, Pediarix, Bexsero |
| Ultragenyx Pharmaceutical INC. | $18.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.53 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.15 | 2025 | Voquezna |
| Dexcom, INC. | $14.88 | 2023 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $14.33 | 2024 | Nuzyra |
| Pfizer INC. | $13.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.